| Literature DB >> 26473489 |
Rupesh Kumar1, Avdhesh Kumar Rai2, Debabrata Das2, Rajjyoti Das3, R Suresh Kumar4, Anupam Sarma5, Shashi Sharma6, Amal Chandra Kataki7, Anand Ramteke1.
Abstract
BACKGROUND: Human papilloma virus (HPV) associated Head and Neck Cancers (HNCs) have generated significant amount of research interest in recent times. Due to high incidence of HNCs and lack of sufficient data on high-risk HPV (hr-HPV) infection from North -East region of India, this study was conceived to investigate hr-HPV infection, its types and its association with life style habits such as tobacco, alcohol consumption etc.Entities:
Mesh:
Year: 2015 PMID: 26473489 PMCID: PMC4608822 DOI: 10.1371/journal.pone.0140700
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
HPV type-specific nested PCR Primer Sequences.
| Primers | Primers (5' to 3') | Amplicon size (bp) | |
|---|---|---|---|
| GP-E6-3F | Sense: GGG AGG TAC TGA AAT CGG T | 630 | |
| GP-E6-6B | Antisense: TCC TCT GAG TCG CCT AAT TGC TC | ||
|
|
|
| |
|
| 16 | Sense: CAC AGT TAT GCA CAG AGC TGC | 457 |
| Antisense: CAT ATA TTC ATG CAA TGT AGG TGT A | |||
| 18 | Sense: CAC TTC ACT GCA AGA CAT AGA | 322 | |
| Antisense: GTT GTG AAA TCG TCG TTT TTC A | |||
| 31 | Sense: GAA ATT GCA TGA ACT AAG CTC G | 263 | |
| Antisense: CAC ATA TAC CTT TGT TTG TCA A | |||
| 59 | Sense: CAA AGG GGA ACT GCA AGA AAG | 215 | |
| Antisense: TAT AAC AGC GTA TCA GCA GC | |||
| 45 | Sense: GTG GAA AAG TGC ATT ACA GG | 151 | |
| Antisense: ACC TCT GTG CGT TCC AAT GT | |||
|
| 33 | Sense: ACT ATA CAC AAC ATT GAA CTA | 398 |
| Antisense: GTT TTT ACA CGT CAC AGT GCA | |||
| 52 | Sense: TAA GGC TGC AGT GTG TGC AG | 229 | |
| Antisense: CTA ATA GTT ATT TCA CTT AAT GGT | |||
| 56 | Sense: GTG TGC AGA GTA TGT TTA TTG | 181 | |
| Antisense: TTT CTG TCA CAA TGC AAT TGC | |||
| 58 | Sense: GTA AAG TGT GCT TAC GAT TGC | 274 | |
| Antisense: GTT GTT ACA GGT TAC ACT TGT | |||
|
| 35 | Sense: CAA CGA GGT AGA AGA AAG CAT C | 358 |
| Antisense: CCG ACC TGT CCA CCG TCC ACC G | |||
| 42 | Sense: CCC AAA GTA GTG GTC CCA GTT A | 277 | |
| Antisense: GAT CTT TCG TAG TGT CGC AGT G | |||
| 43 | Sense: GCA TAA TGT CTG CAC GTA GCT G | 219 | |
| Antisense: CAT GAA ACT GTA GAC AGG CCA AG | |||
| 44 | Sense: TAA ACA GTT ATA TGT AGT GTA CCG | 163 | |
| Antisense: TAT CAG CAC GTC CAG AAT TGA C | |||
|
| 39 | Sense: GAC GAC CAC TAC AGC AAA CC | 280 |
| Antisense: TTA TGA AAT CTT CGT TTG CT | |||
| 51 | Sense: GAG TAT AGA CGT TAT AGC AGG | 223 | |
| Antisense: TTT CGT TAC GTT GTC GTG TAC G | |||
| 66 | Sense: TTC AGT GTA TGG GGC AAC AT | 172 | |
| Antisense: AAA CAT GAC CCG GTC CAT GC | |||
| 68 | Sense: GCA GAA GGC AAC TAC AAC GG | 333 | |
| Antisense: GTT TAC TGG TCC AGC AGT GG |
Demographic profiles and association with hr- HPV Positivity-.
| Characteristic | Total Cases (n = 106) N (%) | hr-HPV positive (n = 33)N (%) | HPV—Negative (n = 73) N (%) | Unadjusted OR [95%CI] | P –value |
|---|---|---|---|---|---|
|
|
| ||||
| Male | 73 (68.86) | 23 (69.70) | 50 (68.49) |
| |
| Female | 33 (31.13) | 10 (30.30) | 23 (31.51) | 0.95 [0.35–2.51] | 0.90 |
|
| |||||
| Non-chewers | 9 (8.18) | 03 (9.10) | 06(8.22) |
| |
| Chewers | 97 (91.82) | 30 (90.90) | 67 (91.78) | 0.90 [0.18–4.89] | 1.00 |
|
| |||||
| Non-chewers | 35 (33.02) | 13 (39.40) | 22 (30.13) |
| |
| Chewers | 71 (66.98) | 20 (60.60) | 51 (69.87) | 0.66 [0.26–1.71] | 0.34 |
|
| |||||
| Non- smokers | 83 (78.30) | 23 (69.69) | 60 (82.19) |
| |
| Smokers | 23 (21.70) | 10 (30.31) | 13 (17.81) | 2.01 [0.70–5.77] | 0.14 |
|
| |||||
| No-intake | 78 (73.58) | 15 (45.45) | 63 (86.30) |
| |
| Intake | 28 (26.42) | 18(55.55) | 10 (13.70) | 7.56 [2.64–22.19] | <0.001 |
|
| |||||
| Non-Intake | 87 (82.07) | 23 (69.69) | 64 (87.67) |
| |
| Intake | 19 (17.93) | 10 (30.31) | 9 (12.33) | 3.09 [1.00–9.65] | 0.02 |
|
| |||||
| Non- smokers | 94 (88.68) | 27 (81.82) | 67 (91.78) |
| |
| Smokers | 12 (11.32) | 6 (18.18) | 6 (8.21) | 2.48 [0.63–9.74] | 0.18 |
|
| |||||
| Vegetarian | 8 (7.54) | 3 (9.09) | 5 (6.49) |
| |
| Non –vegetarian | 98 (92.45) | 30 (90.91) | 68 (93.50) | 0.74 [0.14–4.20] | 0.70 |
|
| |||||
| Urban | 7 (6.36) | 1 (3.03) | 6 (8.21) |
| |
| Semi urban | 14 (13.20) | 3 (9.09) | 11 (15.06) | 1.64 [0.10–51.13] | 1.00 |
| Rural | 85 (80.18) | 29 (87.88) | 56 (76.71) | 3.11 [0.34–71.78] | 0.42 |
|
| |||||
| ≤50 years | 52(49.05) | 16 (48.48) | 36 (49.31) |
| |
| >50 years | 54(50.95) | 17 (51.52) | 37 (50.69) | 1.03 [0.42–2.55] | 0.93 |
* Statistically Significant; OR = odds ratio; CI = confidence interval;
† Reference group for OR calculation. Since only one variable is significant that will be significant in multivariate analysis also
Relationship between clinico-pathological characteristics and hr- HPV Positivity.
| Characteristic | Total Cases (n = 106) N (%) | hr- HPV positive (n = 33) N (%) | hr-HPV Negative (n = 73) N (%) | Unadjusted OR [95%CI] | P –value |
|---|---|---|---|---|---|
|
| |||||
|
| |||||
|
| 86 (81.13) | 24 (72.72) | 62 (84.93) | 4.73[0.17–1.28] | 1.40 |
|
| 9 (8.49) | 2 (6.06) | 7 (9.58) | 0.61[0.11–3.10] | 0.55 |
|
| 3 (2.83) | 2 (6.06) | 1 (1.37) | 4.64[0.40–53.1] | 0.18 |
|
| 5 (4.71) | 5 (15.15) | 0 (0.00) | - | <0.01 |
|
| 3 (2.83) | 0 (0.00) | 3 (4.10) | - | 0.24 |
|
| |||||
|
| 15 (14.15) | 3 (9.09) | 12 (16.45) |
| |
|
| 26 (24.52) | 6 (18.18) | 20 (27.39) | 1.20 [0.20–7.55] | 1.00 |
|
| 59 (55.66) | 24 (72.73) | 35 (47.94) | 2.74[0.62–13.81] | 0.13 |
|
| 6 (5.66) | 0 (0.00) | 6 (8.21) | - | 0.52 |
|
| |||||
|
| 8 (7.54) | 2 (6.06) | 6 (8.21) |
| |
|
| 91 (85.85) | 30 (90.91) | 61 (83.56) | 1.48[0.25–11.31] | 1.00 |
|
| 7 (6.60) | 1 (3.03) | 6 (8.21) | 0.50[0.01–11.02] | 1.00 |
|
| |||||
|
| 74 (69.81) | 21 (63.63) | 53 (72.60) |
| |
|
| 22 (20.75) | 8 (24.24) | 14 (19.17) | 1.44[0.47–4.38] | 0.47 |
|
| 10 (9.44) | 4 (12.12) | 6 (8.21) | 1.68[0.35–7.74] | 0.38 |
* Statistically Significant OR = odds ratio; CI = confidence interval;
† Reference group for OR calculation
Relationship of betel nut, tobacco, smoking, and alcohol and status of hr-HPV in Oral cavity patients only.
| Characteristic | Oral cavity Cases (n = 86) N (%) | hr-HPV positive (n = 24)N (%) | HPV—Negative (n = 62) N (%) | Unadjusted OR [95% CI] | P –value |
|---|---|---|---|---|---|
|
| |||||
|
| |||||
|
| 9 (10.46) | 6 (25) | 3 (4.84) |
| |
|
| 77 (89.54) | 18 (75) | 59 (95.16) | 0.15[0.03–0.79] | 0.01 |
|
| |||||
|
| 30 (34.88) | 10 (41.67) | 20 (32.25) |
| |
|
| 56 (65.12) | 14 (58.33) | 42 (67.75) | 0.67[0.23–1.96] | 0.41 |
|
| |||||
|
| 66 (76.74) | 20 (83.33) | 46 (74.19) |
| |
|
| 20 (23.26) | 4 (16.67) | 16 (25.81) | 0.57[0.14–2.17] | 0.36 |
|
| |||||
|
| 64 (74.42) | 14 (58.33) | 50(80.64) |
| |
|
| 22 (25.58) | 10 (41.67) | 12 (19.36) | 2.98[0.95–9.43] | 0.03 |
|
| |||||
|
| 69 (80.23) | 16 (66.67) | 53 (85.48) |
| |
|
| 17 (19.77) | 8 (33.33) | 9 (14.52) | 2.94 [0.97–8.88] | 0.05 |
|
| |||||
|
| 77 (89.54) | 20 (83.33) | 57 (91.93) |
| |
|
| 9 (10.46) | 4 (16.66) | 5 (8.06) | 2.28 [0.55–9.33] | 0.25 |
* Statistically Significant OR = odds ratio; CI = confidence interval;
† Reference group for OR calculation
Relation of HPV -16 and HPV-18 with clinico-pathological characteristics.
| Characteristic | Total HPV positive (n = 33) N (%) | HPV-16 Positive | HPV-18 Positive | Unadjusted OR [95%CI] | P- value |
|---|---|---|---|---|---|
|
| |||||
|
| |||||
|
| 23 (69.69) | 18 (66.66) | 5 (83.33) |
| |
|
| 10 (30.30) | 9 (33.44) | 1 (16.67) | 2.5[0.21–15.52] | 0.64 |
|
| |||||
|
| 16 (48.48) | 12 (44.44) | 4 (66.67) |
| |
|
| 17 (51.51) | 15 (55.56) | 2 (33.33) | 2.50 [0.30–24.23] | 0.40 |
|
| |||||
|
| 3 (9.09) | 1 (3.70) | 2 (33.34) |
| |
|
| 30 (90.91) | 26 (96.29) | 4 (66.66) | 13.0[0.66–483.12] | 0.08 |
|
| |||||
|
| 13 (39.39) | 8 (29.63) | 5 (83.33) |
| |
|
| 20 (60.60) | 19 (70.37) | 1 (16.67) | 11.88[1.01–317.21] | 0.02 |
|
| |||||
|
| 23 (69.69) | 21(77.78) | 2 (33.33) |
| |
|
| 10 (30.30) | 6 (22.22) | 4 (66.66) | 0.14 [0.01- 1.28] | 0.05 |
|
| |||||
|
| 15 (45.45) | 13(48.15) | 2 (33.33) |
| |
|
| 18 (54.54) | 14 (51.85) | 4 (66.66) | 0.54[0.06–4.43] | 0.51 |
|
| |||||
|
| 24 (72.72) | 19 (70.37) | 5 (83.33) |
| |
|
| 2 (6.06) | 2 (7.41) | 0 (0.00) | - | 0.48 |
|
| 2 (6.06) | 2 (7.41) | 0 (0.00) | - | 0.48 |
|
| 5 (15.15) | 4 (14.82) | 1 (16.66) | 1.05[0.07–30.65] | 0.96 |
|
| |||||
| II | 3 (9.09) | 3 (11.11) | 0 (0.00) | - | |
| III | 6 (18.18) | 4 (14.81) | 2 (33.33) | - | 0.44 |
| IVA | 24 (72.72) | 20 (74.08) | 4 (67.67) | - | |
|
| |||||
|
| 30 (90.90) | 25 (92.59) | 5 (83.34) |
| |
|
| 2 (6.06) | 1 (3.70) | 1 (16.66) | 0.20[0.01–8.93] | 0.24 |
|
| 1 (3.03) | 1 (3.70) | 0 (0.00) | 0.64[0.02–18.0] | 0.65 |
|
| |||||
|
| 21 (63.63) | 18 (66.67) | 3 (50) |
| |
|
| 8 (24.24) | 6 (22.22) | 2 (33.33) | 0.50[0.05–5.69] | 0.49 |
|
| 4 (12.12) | 3 (11.11) | 1 (16.66) | 0.50[0.02–17.07] | 0.59 |
* Statistically Significant, OR = odds ratio; CI = confidence interval;
† Reference group for OR calculation